Ulrif 1 Tablet

About Ulrif 1 Tablet

Ulrif 1 is a 1 gm tablet containing sucralfate, used to treat stomach and duodenal ulcers and chronic gastritis. It works by forming a protective barrier over the ulcer area.

There are 15 brands of Sucralfate listed in Bangladesh. The lowest listed price is Antepsin 1000 mg Tablet at ৳ 5.52 per unit.

What is Ulrif 1 Tablet?

Ulrif 1 is a sucralfate 1 gm tablet made by Square Pharmaceuticals PLC. It belongs to a group of medicines called chelating complexes. Sucralfate is only minimally absorbed from the gut, so it acts mainly at the ulcer site. It binds to the damaged area and forms a protective barrier, and it also reduces the action of pepsin and bile. This helps the ulcer to heal. The doctor will decide the dose and how long you take it, based on your condition.

Uses of Ulrif 1

Ulrif 1 is used in adults and adolescents for the treatment of duodenal ulcer, gastric ulcer, and chronic gastritis. It is also used to help prevent gastrointestinal bleeding caused by stress ulcers in seriously ill patients. Your doctor will decide whether this medicine is suitable for you and will set the dose and course.

How to use Ulrif 1

Take Ulrif 1 exactly as your doctor tells you. The doctor decides the dose, how often to take it, and how long the course lasts. Swallow the tablet as directed. Do not change the dose or stop early without asking your doctor or pharmacist. If you forget a dose, ask your doctor or pharmacist what to do. Keep all appointments for follow-up.

Side effects of Ulrif 1

Some people may get a headache, nausea, stomach pain, constipation, diarrhoea, or a skin rash (urticaria). In some patients, hard masses called bezoars have been reported, mostly in people with conditions that slow stomach emptying or who are on tube feeding. High blood sugar has been reported in diabetic patients. Tell your doctor if you have any side effect that bothers you.

Safety and precautions

Do not take Ulrif 1 if you are allergic to sucralfate. Use it with caution if you have kidney problems, because aluminium may build up; it is not recommended for people on dialysis, and in severe or chronic kidney impairment it should be used with extreme caution and only for short-term treatment. Safety in pregnancy has not been established, so it should be used in pregnancy only if clearly needed. It is not known whether sucralfate passes into breast milk, so caution is needed while breastfeeding. Tell your doctor if you are pregnant, breastfeeding, have kidney disease, or take other medicines.

Frequently asked questions

What is Ulrif 1 used for and what kind of medicine is it?

Ulrif 1 is a sucralfate 1 gm tablet. It is used to treat duodenal ulcer, gastric ulcer, and chronic gastritis, and to help prevent bleeding from stress ulcers in seriously ill patients. It is a chelating complex that forms a protective barrier over the ulcer site.

How should I store Ulrif 1?

Keep the tablets in a cool, dry place, away from light. Store them out of the reach of children. Do not use after the expiry date printed on the pack. If you are unsure how to store it, ask your pharmacist.

Is Ulrif 1 safe in pregnancy or breastfeeding?

Safety in pregnancy has not been established, so it should be used in pregnancy only if clearly needed. It is not known whether sucralfate passes into breast milk, so caution is needed while breastfeeding. Speak to your doctor before taking it if you are pregnant or breastfeeding.

Can Ulrif 1 interact with other medicines?

Yes. Sucralfate may reduce the absorption of some medicines, including certain antibiotics, digoxin, warfarin, phenytoin, theophylline, levothyroxine, and others. Your doctor may ask you to take these medicines at a different time. Tell your doctor or pharmacist about all medicines you take.

Indications

Sucralfate is indicated in adults and adolescents over 14 years old for treatment of-
  • Duodenal ulcer
  • Gastric ulcer
  • Chronic gastritis
  • The prophylaxis of gastrointestinal hemorrhage from stress ulceration in seriously ill patients.

Pharmacology

Sucralfate is non-systemic as the drug is only minimally absorbed from the gastrointestinal tract. The minute amount which absorbed primarily excretes in the urine. Sucralfate promotes the healing of gastric and duodenal ulcers by the formation of a chemical complex that binds to the ulcer site to establish a protective barrier. Besides, Sucralfate inhibits the action of pepsin and bile.

Dosage & Administration

Duodenal ulcer, gastric ulcer, chronic gastritis-
  • Adults: The usual dose is Sucralfate 2 gm twice daily to be taken on rising and at bedtime or Sucralfate 1 gm four times a day to be taken 1 hour before meals and at bedtime. Maximum daily dose is 8 gm but up to twelve weeks may be necessary in resistant cases.
  • Pediatric population: The safety and efficacy of Sucralfate in children under 14 years of age has not been established.
  • Elderly: There are no special dosage requirements for elderly patients but as with all medicines the lowest effective dose should be used.
Prophylaxis of gastrointestinal hemorrhage from stress ulceration-
  • Adults: The usual dose is Sucralfate 1 gm orally or via a nasogastric tube 4 to 6 times a day. To prevent clogging of the nasogastric tube flush with 10 ml of water following each administration. The duration of treatment for prophylaxis of stress ulceration must be individually determined. Treatment should be continued for as long as one or more of the risk factors for stress ulceration is present but normally not for more than 14 days.

Interaction

Concomitant administration of Sucralfate may reduce the bioavailability of certain drugs including Fluoroquinolones such as Ciprofloxacin and Norfloxacin, Tetracycline, Ketoconazole, Sulpiride, Digoxin, Warfarin, Phenytoin, Theophylline, Levothyroxine, Quinidine, and H2 antagonists. The bioavailability of these agents may be restored by separating the administration of these agents from Sucralfate by two hours. This interaction appears to be non-systemic in origin presumably resulting from these agents being bound by Sucralfate in the gastrointestinal tract. Because of the potential of Sucralfate to alter the absorption of some drugs from the gastrointestinal tract, the separate administration of Sucralfate from that of other agents should be considered when alterations in bioavailability are felt to be critical for concomitantly administered drugs. Sucralfate should not be co-administered with citrate preparations. Co-administration citrate preparations with sucralfate may increase the blood concentrations of aluminium. The mechanism may be due to the chelation of aluminium which is assumed to increase its absorption. The administration of Sucralfate   1 g and enteral feeds by nasogastric tube should be separated by one hour in patients receiving Sucralfate 1 g for the prophylaxis of stress ulceration. In rare cases, bezoar formation has been reported when Sucralfate and enteral feeds have been given too closely together.

Contraindications

Sucralfate tablet and suspension are contraindicated in patients with hypersensitivity to sucralfate.

Side Effects

The most common adverse event was headache (3.4%) followed by nausea (2.3%), abdominal pain (2.3%), constipation (1.1%), diarrhea (1.1%), and urticaria (1.1%). The majority of patients who reported bezoars, had underlying medical conditions that may predispose to bezoar formation (such as delayed gastric emptying) or were receiving concomitant enteral tube feedings. Episodes of hyperglycemia have been reported in diabetic patient.

Pregnancy & Lactation

Safety in pregnant women has not been established and Sucralfate should be used during pregnancy only if clearly needed. It is not known whether this drug is excreted in human milk. Caution should be exercised when Sucralfate is administered to breast-feeding women.

Precautions & Warnings

Sucralfate should only be used with caution in patients with renal dysfunction, due to the possibility of increased aluminium absorption. Sucralfate is not recommended for use in individuals on dialysis. In patients with severe or chronic renal impairment, Sucralfate should be used with extreme caution and only for short-term treatment. Small amounts of aluminium are absorbed through the gastrointestinal tract and aluminium may accumulate. Aluminium osteodystrophy, osteomalacia, encephalopathy and anaemia have been reported in patients with chronic renal impairment. For patients with impairment of renal function, laboratory testing such as aluminium, phosphate, calcium and alkaline phosphatase is recommended to be periodically performed due to excretion impairment. The concomitant use of other aluminium containing medications is not recommended in view of the enhanced potential for aluminium absorption and toxicity. Bezoars have been reported after administration of sucralfate mainly to severely ill patients in intensive care units. The majority of these patients (including neonates in whom sucralfate is not recommended) had underlying conditions that may predispose to bezoar formation (such as delayed gastric emptying due to surgery, drug therapy or diseases that reduce motility) or were receiving concomitant enteral tube feeding.

Overdose Effects

In a clinical trial on healthy men of overdose with Sucralfate, most cases remained asymptomatic but symptoms of abdominal pain, nausea, and vomiting were reported in a few cases. Acute oral toxicity studies in animals using doses up to 12 gm/kg body weight could not find a lethal dose. Risks associated with overdose should therefore be minimal.

Storage Conditions

Store in a cool and dry place, protected from light.

Alternative brands of Sucralfate

Other brands with the same generic name, cheapest first.

See all 15 brands

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.